Mark Elliott - Pure Bioscience VP
| PUREDelisted Stock | USD 0.13 0.00 0.00% |
VP
Mr. Mark Elliott is Chief Financial Officer, Chief Accounting Officer, Vice President Finance of the Company. Prior to his appointment, he served as our corporate controller since May 2006, and was responsible for managing all accounting and regulatory reporting activities and for establishing all current financial and reporting systems. Prior to joining PURE in 2004, Mr. Elliott worked in government accounting. He earned a Bachelors of Science, Business AdministrationAccountancy at California State UniversitySan Marcos. since 2015.
| Age | 48 |
| Tenure | 9 years |
| Phone | 619 596 8600 |
| Web | https://www.purebio.com |
Pure Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.6231) % which means that it has lost $0.6231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2879) %, meaning that it created substantial loss on money invested by shareholders. Pure Bioscience's management efficiency ratios could be used to measure how well Pure Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 239 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Pure Bioscience has a current ratio of 1.98, which is within standard range for the sector. Debt can assist Pure Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Pure Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pure Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pure to invest in growth at high rates of return. When we think about Pure Bioscience's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 2 records | VP Age | ||
| Paula Davis | Colgate Palmolive | N/A | |
| Alison Rhoten | Kimberly Clark | N/A | |
Management Performance
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.62 |
Pure Bioscience Leadership Team
Elected by the shareholders, the Pure Bioscience's board of directors comprises two types of representatives: Pure Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pure. The board's role is to monitor Pure Bioscience's management team and ensure that shareholders' interests are well served. Pure Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pure Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Albert Beraldo, Director | ||
| Tom Myers, COO | ||
| Tom CPA, Pres CEO | ||
| Balbir Johal, Director | ||
| William Otis, Independent Director | ||
| David Pfanzelter, Independent Chairman of the Board | ||
| David Theno, Independent Director | ||
| Bhupender Gosain, CFO and Corporate Secretary | ||
| James Boyce, Director | ||
| Dale Okuno, Director | ||
| Geoff Balderson, CFO, Director | ||
| Henry Lambert, CEO and Director | ||
| Thomas Myers, COO Director | ||
| Jane Pagel, Director | ||
| John Kasperski, VP Sales | ||
| Malay Panchal, CEO, Director | ||
| Zhinong Yan, Exec Devel | ||
| Elisabeth Hagen, Independent Director | ||
| Eric Warren, Director | ||
| Chandrakant Panchal, Chairman of the Board | ||
| Ivan Chen, Independent Director | ||
| Tom Lee, Director | ||
| Janet Risi, Independent Director | ||
| Gary Cohee, Director | ||
| Brian ONeill, Director | ||
| Mark Elliott, Principal Financial and Accounting Officer and VP of Fin. | ||
| Erica Bearss, Independent Director |
Pure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pure Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (1.98) % | ||||
| Current Valuation | 13.51 M | ||||
| Shares Outstanding | 111.36 M | ||||
| Shares Owned By Insiders | 41.23 % | ||||
| Number Of Shares Shorted | 222.97 K | ||||
| Price To Earning | 12.49 X | ||||
| Price To Book | 3.85 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pure Bioscience using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Pure Pink Sheet
If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |